Genentech Targeted Drug Helps Lung Cancer -Study (Reuters)


Reuters - Lung cancer patients given Genentech
Inc.'s targeted drug Avastin along with standard chemotherapy
lived longer, the U.S. National Cancer Institute said on
Monday, sending the company's shares up 25 percent and raising
hopes for treatment of an almost always fatal cancer.

Read more...